{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:07Z","timestamp":1786988047286,"version":"build-2736575974"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejim.2024.05.006","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T15:52:21Z","timestamp":1718725941000},"page":"33-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Pharmacotherapy for older people with obesity"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4739-9170","authenticated-orcid":false,"given":"Luke D.","family":"Boyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5091-9160","authenticated-orcid":false,"given":"Feray","family":"Akbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Yaz\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara M.","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Yumuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejim.2024.05.006_bib0001","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/1403494818764810","article-title":"Prevalence and trends of overweight and obesity in older adults from 10 European countries from 2005 to 2013","volume":"46","author":"Peralta","year":"2018","journal-title":"Scand J Public Health"},{"issue":"7","key":"10.1016\/j.ejim.2024.05.006_bib0002","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/BF02982710","article-title":"The danger of weight loss in the elderly","volume":"12","author":"Miller","year":"2008","journal-title":"J Nutr Health Aging"},{"issue":"6","key":"10.1016\/j.ejim.2024.05.006_bib0003","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000442721","article-title":"European guidelines for obesity management in adults","volume":"8","author":"Yumuk","year":"2015","journal-title":"Obes Facts"},{"issue":"5152","key":"10.1016\/j.ejim.2024.05.006_bib0004","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.15585\/mmwr.mm695152a8","article-title":"COVID-19 Stats: COVID-19 Incidence,* by Age Group(\u2020) - united states, march 1-november 14, 2020(\u00a7)","volume":"69","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.ejim.2024.05.006_bib0005","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1016\/j.ejim.2024.05.006_bib0006","doi-asserted-by":"crossref","first-page":"283","DOI":"10.7205\/MILMED-D-14-00636","article-title":"Topiramate-associated weight loss in a veteran population","volume":"181","author":"Kazerooni","year":"2016","journal-title":"Mil Med"},{"issue":"9774","key":"10.1016\/j.ejim.2024.05.006_bib0007","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejim.2024.05.006_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2017.03.004","article-title":"Pharmacokinetics and tolerability of lorcaserin in special populations: elderly patients and patients with renal or hepatic impairment","volume":"39","author":"Christopher","year":"2017","journal-title":"Clin Ther"},{"issue":"13","key":"10.1016\/j.ejim.2024.05.006_bib0009","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1080\/14656566.2018.1511704","article-title":"Selecting appropriate weight loss pharmacotherapies in older adults to reduce cardiovascular risk","volume":"19","author":"Carbone","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.ejim.2024.05.006_bib0010","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/obr.12815","article-title":"Treatment of obesity in older persons-A systematic review","volume":"20","author":"Haywood","year":"2019","journal-title":"Obes Rev"},{"issue":"9","key":"10.1016\/j.ejim.2024.05.006_bib0011","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41574-018-0062-9","article-title":"Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies","volume":"14","author":"Batsis","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.ejim.2024.05.006_bib0012","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1017\/S002966511500169X","article-title":"Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity","volume":"74","author":"Wannamethee","year":"2015","journal-title":"Proc Nutr Soc"},{"issue":"12","key":"10.1016\/j.ejim.2024.05.006_bib0013","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/jbmr.2564","article-title":"Does diet-induced weight loss lead to bone loss in overweight or obese adults? a systematic review and meta-analysis of clinical trials","volume":"30","author":"Zibellini","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.ejim.2024.05.006_bib0014","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ypmed.2004.04.003","article-title":"Barriers and motivations to exercise in older adults","volume":"39","author":"Schutzer","year":"2004","journal-title":"Prev Med"},{"issue":"13","key":"10.1016\/j.ejim.2024.05.006_bib0015","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1080\/14656566.2021.1921150","article-title":"How do you treat obesity in the elderly pharmacologically?","volume":"22","author":"Gonz\u00e1lez","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.ejim.2024.05.006_bib0016","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2012.113905","article-title":"Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis","volume":"309","author":"Flegal","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ejim.2024.05.006_bib0017","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/acel.12207","article-title":"Optimal body weight for health and longevity: bridging basic, clinical, and population research","volume":"13","author":"Fontana","year":"2014","journal-title":"Aging Cell"},{"issue":"23","key":"10.1016\/j.ejim.2024.05.006_bib0018","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1000367","article-title":"Body-mass index and mortality among 1.46 million white adults","volume":"363","author":"Berrington de Gonzalez","year":"2010","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ejim.2024.05.006_bib0019","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1056\/NEJMoa1616338","article-title":"Aerobic or resistance exercise, or both, in dieting obese older adults","volume":"376","author":"Villareal","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2024.05.006_bib0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1467-789X.2006.00248.x","article-title":"Elevated body mass index and mortality risk in the elderly","volume":"8","author":"Janssen","year":"2007","journal-title":"Obes Rev"},{"issue":"8","key":"10.1016\/j.ejim.2024.05.006_bib0021","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJMoa055643","article-title":"Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old","volume":"355","author":"Adams","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejim.2024.05.006_bib0022","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/GME.0000000000001589","article-title":"The association between weight-promoting medication use and weight gain in postmenopausal women: findings from the Women's Health Initiative","volume":"27","author":"Stanford","year":"2020","journal-title":"Menopause"},{"issue":"11","key":"10.1016\/j.ejim.2024.05.006_bib0023","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/qjmed\/hct141","article-title":"The impact of number of drugs prescribed on the risk of potentially inappropriate medication among outpatient older adults with chronic diseases","volume":"106","author":"Weng","year":"2013","journal-title":"QJM"},{"issue":"5","key":"10.1016\/j.ejim.2024.05.006_bib0024","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2165\/00002512-199711050-00002","article-title":"Drug therapy for obesity in the elderly","volume":"11","author":"Dvorak","year":"1997","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1016\/j.ejim.2024.05.006_bib0025","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/archfami.9.2.160","article-title":"Orlistat in the long-term treatment of obesity in primary care settings","volume":"9","author":"Hauptman","year":"2000","journal-title":"Arch Fam Med"},{"issue":"3","key":"10.1016\/j.ejim.2024.05.006_bib0026","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","article-title":"One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor","volume":"24","author":"Finer","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"9","key":"10.1016\/j.ejim.2024.05.006_bib0027","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1210\/clinem\/dgab359","article-title":"Approach to obesity in the older population","volume":"106","author":"Buch","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ejim.2024.05.006_bib0028","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2165\/11536660-000000000-00000","article-title":"Long-term pharmacotherapy for obesity in elderly patients: a retrospective evaluation of medical records from a specialized obesity outpatient clinic","volume":"27","author":"Horie","year":"2010","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.ejim.2024.05.006_bib0029","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF03324798","article-title":"Effects of weight loss on ventricular systolic and diastolic functions and left ventricular mass assessed by tissue doppler imaging in obese geriatric women: preliminary report","volume":"22","author":"Varli","year":"2010","journal-title":"Aging Clin Exp Res"},{"issue":"5","key":"10.1016\/j.ejim.2024.05.006_bib0030","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1054\/npep.1999.0053","article-title":"Glucagon-like peptide-1 (7-36) amide: a central regulator of satiety and interoceptive stress","volume":"33","author":"van Dijk","year":"1999","journal-title":"Neuropeptides"},{"issue":"4","key":"10.1016\/j.ejim.2024.05.006_bib0031","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.05.006_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.endmts.2021.100082","article-title":"An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain","volume":"2","author":"Tof\u00e9","year":"2021","journal-title":"Endocrine and Metabolic Sci"},{"issue":"1","key":"10.1016\/j.ejim.2024.05.006_bib0033","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ejim.2024.05.006_bib0034","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40520-015-0525-y","article-title":"Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study","volume":"28","author":"Perna","year":"2016","journal-title":"Aging Clin Exp Res"},{"issue":"6","key":"10.1016\/j.ejim.2024.05.006_bib0035","doi-asserted-by":"crossref","first-page":"423","DOI":"10.7326\/M18-1569","article-title":"Effect of liraglutide on cardiovascular outcomes in elderly patients: a post hoc analysis of a randomized controlled trial","volume":"170","author":"Gilbert","year":"2019","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.ejim.2024.05.006_bib0036","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.2337\/dc13-0354","article-title":"Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes","volume":"36","author":"Kim","year":"2013","journal-title":"Diabetes Care"},{"issue":"10077","key":"10.1016\/j.ejim.2024.05.006_bib0037","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejim.2024.05.006_bib0038","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejim.2024.05.006_bib0039","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/dom.13125","article-title":"Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials","volume":"20","author":"Davies","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.ejim.2024.05.006_bib0040","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP Trials 1 to 5","volume":"28","author":"Kushner","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"10.1016\/j.ejim.2024.05.006_bib0041","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ejim.2024.05.006_bib0042","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.ejim.2024.05.006_bib0043","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ejim.2024.05.006_bib0044","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.ejim.2024.05.006_bib0045","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejim.2024.05.006_bib0046","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.mayocp.2016.11.001","article-title":"Obesity and heart failure: focus on the obesity paradox","volume":"92","author":"Carbone","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.ejim.2024.05.006_bib0047","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pcad.2015.12.003","article-title":"Update on obesity and obesity paradox in heart failure","volume":"58","author":"Lavie","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.ejim.2024.05.006_bib0048","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2217\/fca-2017-0023","article-title":"Obesity, body composition and cardiorespiratory fitness in heart failure with preserved ejection fraction","volume":"13","author":"Carbone","year":"2017","journal-title":"Future Cardiol"},{"key":"10.1016\/j.ejim.2024.05.006_bib0049","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.nut.2017.08.003","article-title":"An obesity paradox with myocardial infarction in the elderly","volume":"46","author":"Lavie","year":"2018","journal-title":"Nutrition"},{"issue":"12","key":"10.1016\/j.ejim.2024.05.006_bib0050","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejim.2024.05.006_bib0051","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1111\/dom.13331","article-title":"Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1-5 trials","volume":"20","author":"Warren","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.ejim.2024.05.006_bib0052","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.rce.2023.05.007","article-title":"Approach to obesity in the elderly population: a consensus report from the Diabetes, Obesity and Nutrition Working Group of SEMI (Spanish Society of Internal Medicine)","volume":"223","author":"P\u00e9rez Mart\u00ednez","year":"2023","journal-title":"Rev Clin Esp (Barc)"},{"issue":"2","key":"10.1016\/j.ejim.2024.05.006_bib0053","article-title":"The Impact of GLP1 agonists on bone metabolism: a systematic review","volume":"58","author":"Daniilopoulou","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"10.1016\/j.ejim.2024.05.006_bib0054","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000491797","article-title":"The effects of electrical acupuncture and essential amino acid supplementation on sarcopenic obesity in male older adults: a randomized control study","volume":"11","author":"Zhou","year":"2018","journal-title":"Obes Facts"},{"issue":"6","key":"10.1016\/j.ejim.2024.05.006_bib0055","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/jcsm.12639","article-title":"Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort","volume":"11","author":"Rooks","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"9","key":"10.1016\/j.ejim.2024.05.006_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.jamda.2021.04.015","article-title":"Intranasal oxytocin improves lean muscle mass and lowers ldl cholesterol in older adults with sarcopenic obesity: a pilot randomized controlled trial","volume":"22","author":"Espinoza","year":"2021","journal-title":"J Am Med Dir Assoc"},{"issue":"11","key":"10.1016\/j.ejim.2024.05.006_bib0057","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40266-017-0496-0","article-title":"The Potential of \u03b2-Hydroxy-\u03b2-Methylbutyrate as a new strategy for the management of sarcopenia and sarcopenic obesity","volume":"34","author":"Rossi","year":"2017","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.ejim.2024.05.006_bib0058","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10403","key":"10.1016\/j.ejim.2024.05.006_bib0059","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"issue":"10317","key":"10.1016\/j.ejim.2024.05.006_bib0060","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"issue":"7504","key":"10.1016\/j.ejim.2024.05.006_bib0061","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/bmj.38446.466238.E0","article-title":"Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study","volume":"330","author":"Whitmer","year":"2005","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ejim.2024.05.006_bib0062","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/02699052.2019.1587000","article-title":"GLP-1\u2032s role in neuroprotection: a systematic review","volume":"33","author":"Erbil","year":"2019","journal-title":"Brain Inj"},{"issue":"12","key":"10.1016\/j.ejim.2024.05.006_bib0063","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40618-014-0137-y","article-title":"GLP-1: benefits beyond pancreas","volume":"37","author":"Muscogiuri","year":"2014","journal-title":"J Endocrinol Invest"},{"issue":"1\u20133","key":"10.1016\/j.ejim.2024.05.006_bib0064","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejphar.2008.03.025","article-title":"GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid","volume":"587","author":"Gault","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.ejim.2024.05.006_bib0065","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/JIM.0000000000000129","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes","volume":"63","author":"Xu","year":"2015","journal-title":"J Investig Med"},{"key":"10.1016\/j.ejim.2024.05.006_bib0066","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neuropharm.2014.07.015","article-title":"Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease","volume":"86","author":"McClean","year":"2014","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.ejim.2024.05.006_bib0067","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jval.2016.08.734","article-title":"Costs and outcomes of increasing access to bariatric surgery: cohort study and cost-effectiveness analysis using electronic health records","volume":"20","author":"Gulliford","year":"2017","journal-title":"Value Health"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524001924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524001924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T08:09:12Z","timestamp":1733126952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524001924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":67,"alternative-id":["S0953620524001924"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.05.006","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy for older people with obesity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}